Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCD for Invasive Candidiasis and Invasive Aspergillosis
NCT04225195Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2020
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
01
Overview
Phase 2, open-label, single-arm trial of amphotericin b cholesteryl sulfate complex in invasive candidiasis and invasive aspergillosis (IA), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Number of patients who discontinued treatment due to study drug-related adverse events or abnormal laboratory tests, Overall response success rate at the end of ABCD treatment and 1 more. Status: unknown.
02
Drugs
amphotericin b cholesteryl sulfate complex
03
Conditions
invasive candidiasisinvasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT04225195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225195.